Cooxygenation by prostaglandin cyclooxygenase from rabbit inner medulla  by Zenser, Terry V. et al.
Kidney International, Vol. 16 (1979), pp. 688-694
Cooxygenation by pro staglandin cyclooxygenase from
rabbit inner medulla
TERRY V. ZENSER, MICHAEL B. MATTAMMAL, WENDY W. BROWN, and
BERNARD B. DAVIS
Departments of Biochernistn' and Medicine, St. Louis University School of Medicine and Geriatric Research, Education
and Clinical Center, Veterans Administration Medical Center, St. Louis, Missouri
Cooxygenation by prostaglandin cyclooxygenase from rabbit in-
ner medulla. The renal inner medulla may be exposed to high
concentrations of organic compounds which are excreted into
the urine. This report examines the capacity of the inner medulla
to metabolize organic compounds both in vitro and in vivo. The
compounds used were l,3-diphenylisobenzofuran (DPBF), lumi-
nol, and benzidine. The inner medulla was shown to possess the
capacity to oxidize each of these compounds. Microsomal oxy-
genation did not require NADPH. Cytochrome P-450 inhibitors
carbon monoxide and metyrapone did not reduce DPBF metabo-
lism. Lipoxygenase activity was not detected in inner medullary
microsomes. Oxygenation of DPBF was demonstrated in inner
medullary slices and was inhibited by indomethacin. The product
of DPBF metabolism in renal slices and microsomes was identi-
fied as O-dibenzoylbenzene. In vivo experiments demonstrated
benzidine metabolism, which was blocked by meclofenamic
acid. On the basis of substrate specificity and inhibitor studies, it
was concluded that oxygenation of DPBF, luminol, and ben-
zidine was mediated by prostaglandin cyclooxygenase. These re-
suIts are compatible with cooxygenation being a mechanism of
inner medullary drug metabolism.
Cooxygénation par Ia prostaglandine cyclooxygénase de Ia me-
dullaire interne du lapin. La médullaire interne du rein peut être
exposée a des concentrations élevées de composes organiques
qui sont excrétés dans l'urine. Ce travail étudie la capacité de Ia
médullaire interne de métaboliser les composes organiques a Ia
fois in vitro et in vivo. Les composes utilisés sont le 1,3-diphény-
lisobenzofurane (DPBF), le luminol, et Ia benzidine. Ii a été
montré que Ia médullaire interne a Ia capacité d'oxyder chacun
de ces trois composes. L'oxygenation microsomale n'exige pas
Ic NADPH. Les inhibiteurs du cytochrome P-450, oxyde de car-
bone et metyrapone, ne réduisent pas le métabolisme de DPBF.
Aucune activité de lipoxygénase n'est détectée dans les micro-
somes de Ia médullaire interne. L'oxygénation de DPBF est dé—
montrée dans les tranches médullaires internes, elle est inhibée
par l'indométhacine. Le produit du métabolisme de DPBF dans
les tranches et les microsomes a été identiflé : II s'agit du 0-
dibenzoylbenzène. Les experiences in vivo démontrent le me-
tabolisme de Ia benzidine, lequel est bloqué par l'acide meclo-
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fénamique. Sur Ia base de Ia spécificité du substrat et des etudes
d'inhibition ii a été conclu que l'oxygénation de DPBF, du lumi-
no!, et de la benzidine a pour médiateur Ia prostaglandine cy-
clooxygénation pour le métabolisme des drogues dans Ia médul-
laire interne.
A number of pharmacologic agents cause nephro-
toxic reactions [1, 2]. Some of these adverse reac-
tions have been related to the oxidative metabolism
of the drugs to a more active form within the kidney
[2-4]. It has been proposed that the mixed-function
oxidase system is a potential pathway for the acti-
vation of these pharmacologic agents [2]. Specific
mixed-function oxidase enzymes, such as aryl hy-
drocarbon hydroxylase and aminopyrine demethy-
lase, have been reported in the rabbit renal cortex
and outer medulla. Similar enzymatic activities
were not observed in the inner medulla [5]. None-
theless, adverse reactions to drugs do occur within
the inner medulla [6, 7], and slices of inner medulla
have been shown to covalently bind drugs [8].
Therefore, an alternative pathway for the activation
of drugs might exist within the inner medulla. In this
regard, vesicular gland prostaglandin cyclooxy-
genase recently has been shown to possess the
capacity to cooxidize certain compounds [9, 10].
In addition, the tumor-promoting phorbol-12,13-
diesters and polycyclic hydrocarbon carcino-
gens stimulate cultured dog kidney cells to produce
prostaglandins [11, 12]. The major portion of renal
prostaglandin synthesis occurs in the inner medulla
[13]. The present study examines the possibility
that the renal inner medulla possesses the capacity
for cooxidation reactions. In vitro and in vivo ex-
periments were designed to investigate the oxida-
tion of the model compounds 1,3-diphenyl-
isobenzofuran (DPBF) and luminol and the urinary
bladder carcinogen and nephrotoxin benzidine.
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Toxic effects of benzidine have been attributed to
its activation following oxidation [14].
Methods
Rabbits were anesthetized with sodium thiopen-
tal, 20 mg/kg, i.v. Kidneys were quickly removed
and were placed in ice-cold 0.85% sodium chloride.
The inner medulla, outer medulla, and cortex were
separated by careful dissection. Slices were washed
twice in cold saline, minced, washed free of hemo-
globin, and homogenized for 15 sec with a polytron
homogenizer in 3 volumes of 0.1 M phosphate buffer
(pH, 7.8) containing 20% glycerol and 0.1 mM di-
thiothreitol. The homogenate was centrifuged at
x 10,000g for 15 mm and the subsequent supernatant
at X 100,000g for 60 mm. The microsomal pellet was
resuspended in 0.1 M phosphate buffer (pH, 7.8) to
give a protein concentration of 10 mglml [5]. Protein
content was estimated by the method of Lowry et al
[15]. The rate of oxygenation of DPBF was deter-
mined by the decrease in absorbancy at 420 nm, at
25° C, in the dark [10]. Kinetic measurements were
made using a Beckman Acta VI recording spectro-
photometer, with a scale expander and a temper-
ature control device. The reaction mixture con-
tained 0.3 mg/mi of .microsomal protein, 0.1 M phos-
phate buffer (pH, 7.8), 0.05 mivi DPBF, and various
test substances in a final volume of 0.2 ml. This re-
action was linear with respect to protein concentra-
tion and, as shown in Fig. 1, with respect to time.
Inhibitors were added to both the sample and refer-
ence cuvettes. The product of oxygenation of
DPBF was characterized by extracting the incuba-
tion mixture with ethyl acetate and evaporating to
dryness under nitrogen gas. Unknown samples and
standards were applied to silica gel F-254 plates
(E. M. Laboratories, Inc., Elmsford, New Jersey)
and developed with benzene and ethanol (90:10,
volume to volume). Samples were then redissolved
in 0.02 ml of acetone. The product was analyzed
and quantitated by gas chromatography using a 10%
OV-1 (methyl silicone) column on Gas-Chrome Q
(80—100) operated at 245° C, with a Hewlett-Packard
instrument (model 5830A), equipped with a flame
ionization detector and an electronic integrator.
Hydrogen, air, and nitrogen flows were 30, 250, and
30 mi/mm. An authentic sample of O-dibenzoylben-
zene was used as the reference (R = 5.4 mm). As-
sessment of DPBF cooxidation was similar with ei-
ther spectroscopic or gas chromatograph tech-
niques. In a representative experiment, the rate of
DPBF metabolism was 11.1 and 10.3 nmoles/mg of
protein/mm by the optical and chromatographic
methods, respectively.
Oxygenation of luminol was determined by mon-
itoring the decrease in chemiluminescence in a
Searle Mark III (model 6880) liquid scintillation
spectrometer [10]. The reaction mixture contained
0.3 mg of microsomal protein, 0.1 M phosphate buf-
fer (pH, 7.8), 110 U of catalase, 0.05 mi luminol,
and various test substances in a final volume of 1
ml. Scintillation counts were recorded at 1-mm in-
tervals for 5 mm. Vials containing only micro-
somes, luminol, and catalase were considered
blanks. Calculated values for luminol oxidation
were obtained by substracting these blank values
from observed scintillation counts. The reaction
was linear with respect to time and protein concen-
tration. Cytochrome P-450 was determined from the
carbon monoxide difference spectrum of dithionite-
reduced microsomes by the method of Omura and
Sato [16].
For the determination of benzidine metabolism,
the reaction mixture contained 0.5 to 2 mg/mi of mi-
crosomal protein, 0.1 m phosphate buffer (pH,
7.8), 0.03 m 14C-benzidine (0.25 .tCi), and various
test substances in a final volume of 0.25 ml at 37° C
for 15 mm. The reaction was linear with time and
protein concentration between 5 and 15 mm of in-
cubation with 0.03 mr'vi benzidine and 0.068 mM
arachidonic acid. The reaction was stopped by addi-
tion of 0.75 m unlabeled benzidine and 0.5 ml of
ethyl acetate and diethyl ether (1:1, volume to vol-
ume). The reaction mixture was extracted until the
radioactivity in the organic phase reached a con-
stant value (approximately eight extractions per
sample). Of the radioactivity recovered in the or-
ganic phase, greater than 92% was judged to be au-
DPBF + microsomes
0.05 zAbsorbance
420 nm
Ethoxyqu in
Arachidonic acid
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Fig. 1. Arachidonic acid-dependent cooxidation of 1 ,3-diphenvl-
isobenzofuran (DPBF) by rabbit inner medullary prostaglandin
cyclooxygenase. As indicated. 0.05 mi DPBF, 0.025 mrvi arachi-
donic acid, and 0.1 mrt ethoxyquin were added to inner medul-
lary microsomes. Oxidation of DPBF was measured by the de-
crease in absorbancy at 420 nm.
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thentic benzidine by thin-layer chromatographic
analysis. These samples were applied to silica gel
plates and developed with methyl ethyl ketone and
N,N-diisopropylethylamine (85:5) or benzene and
ethanol (70:30), with RF values for benzidine of 0.70
and 0.53, respectively. The radioactivity remaining
in the aqueous phase was determined and consid-
ered to be metabolized 14C-benzidine. In the pres-
ence of 0.068 mrvi arachidonic acid, approximately
30% of the total benzidine present in the reaction
mixture was metabolized.
Reaction mixtures containing DPBF, luminol,
and 14C-benzidine were started by the addition of
fatty acid. Inhibitors were preincubated with micro-
somes for 5 mm at room temperature prior to addi-
tion of fatty acid. Figure 1 illustrates that certain
inhibitors such as ethoxyquin can cause an immedi-
ate inhibition of cooxidation and prostaglandin syn-
thesis. Other inhibitors, such as aspirin, required
preincubation to quantitate inhibition [17]. There-
fore, the 5 mm' s preincubation of inhibitors and mi-
crosomes was utilized to obtain an accurate assess-
ment of inhibition. In most cases, only results with
maximally effective concentrations of inhibitors are
provided to make interpretation straight-forward.
All inhibitors and initiators of cooxidation were
found to elicit their respective effects in a dose-de-
pendent manner.
For determination of microsomal synthesis of
prostaglandin E2 (PGE2), the reaction mixture con-
tained 0.5 mg/mi protein, 0.1 m phosphate buffer
(pH, 7.8), 0.0025 mi 3H-arachidonic acid (New
England Nuclear), and various concentrations of
DPBF or O-dibenzoyibenzene in a final volume of
0.1 ml at 37° C for 10 mm. The reaction was stopped
by the addition of 0.009 ml of 1 N hydrochloric acid.
Heated microsomes were used as blanks. Following
addition of 0.4 ml of saturated sodium chloride solu-
tion, the pH was adjusted to 2.5 to 3.5, extracted
with ethyl acetate, and evaporated to dryness under
nitrogen gas. Samples were applied to silica gel F-
254 plates (EM Laboratories) and developed in a
solvent system containing chloroform, methanol,
and acetic acid (90:5:5). Standards were identified
with iodine vapors, and the radioactivity was deter-
mined in corresponding zones.
For in vivo experiments, dogs were anesthetized
with sodium pentothal, 30 mg/kg. The bladder was
exteriorized through a suprapubic incision, and
both ureters were catheterized. '4C-Benzidine, 0.03
mM (2 jsCi), was injected into the renal pelvis
through the ureteral catheter. The vehicle was 4 ml
of 0.85% sodium chloride containing 0.1 mvi arachi-
donic acid. The catheter was then clamped for 5
mm. After the clamp on the ureteral catheter was
released, urine was collected at 5-mm intervals for
30 mm. Urine was adjusted to a pH of 7 to 8 and
then extracted as described above.
For slice experiments, rabbit kidneys were bi-
sected in the sagittal plane, and slices obtained with
a Stadie-Riggs microtome were placed on filter pa-
per moistened with ice-cold 0.85% sodium chloride
[18]. Each slice was carefully dissected to isolate
the inner medulla, which was washed twice in sa-
line. The moist tissue was weighed to the nearest
milligram on an analytic balance. Slices weighing 40
to 60 mg were placed in a 25-mi flask containing 2 ml
of incubation medium. The medium consisted of
Krebs-Ringer bicarbonate buffer at a pH of 7.4 con-
taining I mglml glucose, 0.5 mM arachidonic acid,
and 0.05 m DPBF. The slices were incubated for
15 mm with 95% oxygen and 5% carbon dioxide.
Slices and media were extracted, applied to thin-
layer chromatographic plates, and analyzed for 0-
dibenzoylbenzene by gas chromatography as de-
scribed above. The possible contribution of plate-
lets to effects observed in the present study is un-
likely because (1) inner meduliary slice radioimmu-
noassayable PGE2 production [18] was not altered
by perfusion of kidneys with saline in situ and (2) in
[l-'4C]-arachidonic acid prelabeled slices, there was
no '4C-label attributable to the major products of
platelet arachidonic acid metabolism, l2L-hydroxy-
5,8,10, 14-eicosatetraenoic acid (HETE), 12-hy-
droxy-5 ,8, lO-heptodecadienoic acid (HHT), or 8-( 1-
hydroxy-3-oxypropyl)-9, 12 L-hydroxyl-5, lO-hepta-
decadienoic acid (thromboxane B2) [19]. All experi-
ments were performed on at least two occasions.
Results represent the mean SEM of at least three
samples from representative experiments. Statisti-
cal differences were evaluated by Student's t test
for unpaired values.
Materials. Metyrapone, indomethacin, dithio-
nite, benzidine dihydrochloride, catalase (beef
liver), 11,14,1 7-eicosatrienoic acid, 9-octadecae-
noic acid, and 9,12,15-octadecatrienoic acid were
purchased from Sigma Chemical Co., St. Louis,
Missouri. 1 ,3-Diphenylisobenzofuran, 0-dibenzoyl-
benzene, luminol, and aspirin (acetylsalicylic acid)
were obtained from Aldrich Chemicals, Milwaukee,
Wisconsin. 5,8,11, 14-Eicosatetraenoic acid and
8,11, l4-eicosatrienoic acid were purchased from
Nu Check Prep, Inc., Elysian, Minnesota. Gas mix-
tures were obtained from Liquid Carbonic, St.
Louis, Missouri. ['4C]-Benzidine (uniformly labeled)
(0.13 mCi/mg) was purchased from New England
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Fig. 2. Difference spectra of dithionite-reduced, carbon monox-
ide-treated microsomes from renal cortex and inner medulla.
In A, cortical microsomes (3.0 mg/mI) were reduced with dith-
ionite and divided between two cuvettes. The sample cuvette
was treated with carbon monoxide, and the difference spectrum
was recorded. In B, inner medullary microsomes (2.5 mg/mI)
were treated as described above.
Nuclear, Boston, Massachusetts. Prostaglandin E2
and H2 were gifts from Drs. John Pike and Robert
Gorman, respectively, of The Upjohn Company,
Kalamazoo, Michigan; 5,8,11, 14-eicosatetraynoic
acid, from Dr. W. E. Scott, Hoffmann-LaRoche,
Nutley, New Jersey; and ethoxyquin, from Dr. G.
L. Romoser, Monsanto Chemical Co., St. Louis,
Missouri. All other chemicals were purchased in the
highest possible grade from standard sources. Male
New Zealand rabbits, each weighing 1.5 to 2.0 kg,
were obtained from Eldridge Laboratory Animals,
Barnhart, Missouri.
Results
Spectral analysis of cortical and inner medullary
microsomes for cytochrome P-450 is shown in Fig.
2. Cortical microsomes exhibited a characteristic
cytochrome P-450 spectra. The calculated cortical
cytochrome P-450 content was 0.08 0.01 nmoles/
mg of protein. By contrast, the characteristic cyto-
chrome P-450 spectra was not detected for either
inner medullary (Fig. 2) or outer medullary micro-
somes (not shown).
Metabolism of DPBF, luminol, or 14C-benzidine
by inner medullary microsomes required specific
fatty acids (Table 1). 5,8,11, l4-Eicosatetraenoic
acid (arachidonic acid) initiated a concentration-de-
pendent metabolism of each of these compounds.
Although the unsaturated fatty acid 8,11, 14-eico sat-
rienoic acid, the precursor of the monoenoic prosta-
glandins, was also effective in initiating metabolism
of DPBF and benzidine, other unsaturated fatty
acids were not effective. Prostaglandin H2 (PGH2),
a prostaglandin cyclic endoperoxide intermediate,
and PGE2, the major product of inner medullary
prostaglandin synthesis, had no effect. The product
of arachidonic acid-mediated DPEF metabolism
was determined by gas chromatography to be O-di-
benzoylbenzene.
Inhibitors of prostaglandin cyclooxygenase inhib-
ited arachidonic acid-dependent metabolism of
DPBF, luminol, or 14C-benzidine (Table 2). Aspirin
(1 mM), indomethacin (0.03 mM), and meclofenamic
acid (0.1 mM) each caused complete inhibition of
metabolism of DPBF, luminol, or 14C-benzidine.
5,8,11,l4-Eicosatetraynoic acid is an acetylene ana-
logue of arachidonic acid. This analogue caused a
70% reduction in DPBF metabolism at 0.025 mM
and completely inhibited DPBF, luminol, or 14C-
benzidine metabolism at 0.1 m. The antioxidant
ethoxyquin (0.1 mM) completely inhibited metabo-
lism of all three compounds. As shown in Fig. 1,
ethoxyquin caused an immediate inhibition of
DPBF cooxidation. Heated microsomes (3 mm at
100° C) did not metabolize any of the three com-
pounds. The specific mixed-function oxidase inhib-
itors, carbon monoxide and metyrapone (1 mM),
were each ineffective in inhibiting DPBF metabo-
lism. The effects of DPBF and O-dibenzoylbenzene
on microsomal PGEZ synthesis was examined.
DPBF and O-dibenzoylbenzene elicited dose-re-
lated inhibition of PGE2 synthesis. The ID50 for both
compounds was approximately 0.05 mM.
Metabolism of DPBF was observed in renal inner
medullary slices (Fig. 3). In slices incubated with
0.05 mM DPBF for 15 mm, the oxidative rate was
545 25 pmoles/mg of wet tissue weight. This me-
tabolism was completely inhibited by 0.28 mivt indo-
methacin. There was no measurable metabolism of
DPBF by slices under anaerobic conditions. As
shown with the microsomal preparations, O-diben-
zoylbenzene was the product of DPBF oxidation.
The major portion of this metabolite was observed
in the media.
In vivo metabolism of benzidine was investigated
by retrograde perfusion of 14C-benzidine in a solu-
tion containing 0.1 mM arachidonic acid. Urinary
collections revealed that 30% of the radioactivity
A = Cortical microsomes
B = Inner medullary microsomes
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was not extracted by ethyl acetate and ether (1:1,
volume to volume). Treatment of dogs for 30 mm
with sodium meclofenamate (5 mg/kg, i.v.) has been
shown to completely inhibit renal prostaglandin
synthesis [20]. Dogs similarly treated with sodium
meclofenamate did not metabolize '4C-benzidine.
Extractions of 14C-benzidine in urinary samples from
meclofenamate-treated dogs were similar to control
samples of urine containing 14C-benzidine and ara-
chidonate.
Discussion
These data indicate that the renal inner medulla
possesses the capacity to metabolize 1 ,3-diphenyl-
isobenzofuran, luminol, and benzidine in the pres-
ence of suitable fatty acid substrates. This oxidation
does not appear to be due to lipoxygenase enzymes.
Lipoxygenases are not inhibited by nonsteroidal
antiinflammatory drugs. In addition, fatty acids
such as 9,12, l5-ocatadecatrienoic acid and
11,14, 17-eicosatrienoic acid, which are substrates
for lipoxygenase [21], did not facilitate DPBF, lumi-
nol, or benzidine metabolism (Table 1). Thin-layer
chromatographic analysis of [1- 14C]-arachidonic
acid metabolism by inner medullary microsomes
did not reveal products characteristic of the lipoxy-
genase reaction.
The oxidation of DPBF, luminol, or benzidine was
independent of mixed function monoxygenases.
The inner medulla does not contain spectrally de-
tectable cytochrome P-450, a component of mixed
function monoxygenase systems (Fig. 2). In addi-
tion, carbon monoxide and metyrapone, which are
known cytochrome P-450 inhibitors [22, 23], did not
Table!. Fatty acid substrate requirement for the cooxygenation of 1,3-diphenylisobenzofuran, luminol, and l4Cbenzidinea
I ,3-Diphenyliso- Luminol
benzofuran intensity of '4C-Benzidine
Conc. nmoles oxidized! chemiluminescence pmoles oxidized!
Additions mi mg protein!min counts per minute mgprotein!min
None — ND ND ND
5,8,11,14-Eicosatetraenoic 0.008 3.3 0.3 7,800 750
acid (arachidonic acid) 0.016
0.024
0.034
0.068
7.2 0.4
11.2 0.5
14,400 930
21,000 1100
185 14
355 9
5,8,11,14-Eicosatetraynoic acid 0.025 ND ND
11,14,17-Eicosatrienoicacid 0.025 ND ND ND
8,11,14-Eicosatrienoic acid 0.025 12.0 0.4 230 12
9-Octadecaenoic acid 0.025 ND
9,12,15-Octadecatrienoicacid 0.025 ND ND ND
Prostaglandin 112 0.025 ND
Prostaglandin E2 0.025 ND ND ND
a ND = not detected.
Table 2. Effect of various compounds on arachidonic acid-dependent 1 ,3-diphenylisobenzofuran, luminol, and '4C-benzidine oxidationa
I ,3-Diphenyliso- Luminol
benzofuran intensity of 14C-Benzidine
Additions Conc.
mM
nmoles oxidized!
mg protein!min
chemiluminescence
counts per minute
pmoles oxidized!
mg protein!min
None — 11.4 0.6 24,100 1300 325 24
Heated microsomes — ND ND ND
Indomethacin 0.03 ND ND ND
Aspirin 1.0 ND ND ND
5,8,11, 14-
Eicosatetraynoic acid
Ethoxyquin
0.025
0.1
0.1
3.4 0.2
ND
ND
ND ND
ND
Meclofenamic acid 0.1 ND ND ND
Metyrapone 1.0 11.8 0.8
Carbon monoxideb 10.9 0.7
a The concentration of arachidonic acid in the incubation mixtures for 1 ,3-diphenylisobenzofuran, luminol, and 14C-benzidine was
0.025 mM, 0.025 m, and 0.068 ms, respectively. ND = not detected.
Carbon monoxide was bubbled into dithionite-reduced microsomal suspensions for 30 sec, divided into equal parts, and used in the
reference and sample curvettes.
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Fig. 3. Metabolism of) ,3-diphenylisobenzofuran (DPBF) by in-
ner medullary slices. Slices were incubated as described in the
Methods section with 50 M DPBF. The gas phase during the
incubation was either 5% carbon dioxide and 95% oxygen or 5%
carbon dioxide and 95% nitrogen (0% oxygen) as indicated. The
gas phase used with 0.28 msi indomethacin was 5% carbon diox-
ide and 95% oxygen.
inhibit arachidonic acid-mediated DPBF metabo-
lism. Furthermore, cytochrome P-450 cofactors,
such as NADPH, were not required for DPBF, lu-
minol, or benzidine metabolism.
Prostaglandin cylooxygenase appears to be medi-
ating the oxidations of DPBF, luminol, and ben-
zidine by the inner medulla. Substrate specificities
for the oxidation of these organic compounds exhib-
ited the same specificity as prostaglandin cy-
clooxygenase. Fatty acid substrates for prostaglan-
din cyclooxygenase have in common the location of
the triene system which terminates at the sixth car-
bon from the alkyl terminus [24]. In addition, non-
steroidal antiinfiamrnatory drugs, 5,8,11, 14-eicosa-
tetraynoic acid (an acetylene analogue of arachi-
donic acid), and an antioxidant, all known to effect
prostaglandin cyclooxygenase activity [25], also in-
hibited cooxidation. Prostaglandin G2 (PGG2) is the
hydroperoxy prostaglandin cyclic endoperoxide in-
termediate which produces PGH2 from arachidonic
acid substrate. Previous studies by Marnett, Wloda-
wer, and Samuelsson have demonstrated that PGG2
is the active intermediate in this cooxidative pro-
cess, and our results are consistent with this con-
clusion [10]. The precise mechanism (that is, free
radical, singlet oxygen, or superoxide anion,) by
which cooxidation occurs has not been clarified. It
appears that DPBF is more effectively cooxidized
than benzidine is. The higher cooxidation rate ob-
served with DPBF may be related to the ease with
which DPBF undergoes oxidation [26]. The ob-
served inhibition of PGE2 synthesis by DPBF is
consistent with previous studies by Marnett et al
[10] and provides additional evidence of the inter-
action of this compound with the prostaglandin-syn-
thetizing system.
These experiments demonstrate that cooxygena-
tion by prostaglandin synthetase can proceed in an
intact cell system. Previous reports of the cooxy-
genation reaction utilized only microsomes pre-
pared from the ram seminal vesicle [9, 10]. The in
vivo experiments demonstrated benzidine metabo-
lism and the in vitro slice experiments conversion of
DPBF to O-dibenzoylbenzene. Therefore, ben-
zidine and DPBF have access to the cyclooxy-
genase enzyme in intact tissue, and the products
are released from the tissue. These products have
access to other cells in the inner medulla and the.
extrarenal collecting system.
The small size of the inner medulla and the rela-
tively low rate of inner medullary blood flow com-
pared to other tissues such as liver and renal cortex
make it unlikely that the inner medullary drug me-
tabolism has an important role in systemic pharma-
cokinetics. The results of this metabolism, how-
ever, could have important consequences in the in-
ner medulla and perhaps the extrarenal collecting
system. In this respect, the inner medulla presents a
unique environment for drug metabolism. Certain
drugs such as acetaminophen have been shown to
be concentrated in the inner medulla [27, 28], and it
has been postulated that such agents are metabo-
lized to more active forms within the inner medulla
[2—4, 7]. The presence of a drug metabolizing sys-
tem in an area of the body that is subject to high
concentrations of certain pharmacologic agents
could be of significance.
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